Favezelimab/Pembrolizumab Drug Due Diligence Report 2026

This Favezelimab/Pembrolizumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 24 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 3

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Favezelimab/Pembrolizumab can convert its Monoclonal antibody profile and LAG3 x PD-1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Favezelimab/Pembrolizumab (query alias: Favezelimab/Pembrolizumab)
Modality / target	Monoclonal antibody; LAG3 x PD-1; LAG3 inhibitors, PD-1 inhibitors
Highest global status	Phase 3
Originator	Merck Sharp & Dohme Corp.
Active developers	Merck Sharp & Dohme Corp., MSD R&D (China) Co. Ltd., Merck Sharp & Dohme LLC

The MCP disease footprint includes Adenocarcinoma of large intestine, Metastatic Colorectal Carcinoma, Cutaneous Squamous Cell Carcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT03486873	Phase 3	Recruiting	3500	Overall Survival (OS)
NCT03516981	Phase 2	Completed	245	Objective Response Rate (ORR)
NCT03598608	Phase 1/2	Completed	137	Percentage of Participants Experiencing a Dose-limiting Toxicity (DLT)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Evidence gap

The Clinical Trials MCP returned no matched public result record. This is a gating diligence gap, not evidence of failure.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Favezelimab/Pembrolizumab addresses Adenocarcinoma of large intestine, Metastatic Colorectal Carcinoma, Cutaneous Squamous Cell Carcinoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 27 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: LAG3 x PD-1 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2025-12-08	Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa	Phase 3	US$20.0M upfront; US$349.5M milestones
2025-02-04	Agenus received formal notice from Incyte electing to terminate the License, Development, and Commercialization Agreement	Phase 2	US$25.0M upfront; US$510.0M milestones
2024-10-07	嘉和生物与亿腾医药宣布合并	Phase 1	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Co-formulations of Anti-LAG3 antibodies and Anti-PD-1 antibodies”. The milestone feed surfaced a patent-application signal described as “Formulations of Anti-LAG3 antibodies and co-formulations of Anti-LAG3 antibodies and Anti-PD-1 antibodies”. The milestone feed surfaced a patent-application signal described as “Anti-LAG3 antibodies and antigen-binding fragments”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO